Literature DB >> 2564824

Antibody 12-15 cross-reacts with mouse Fc gamma receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein.

P Altevogt1, U Kohl, P Von Hoegen, E Lang, V Schirrmacher.   

Abstract

Previously we described a monoclonal antibody (mAb 12-15) that reacted with murine Fc receptor proteins (beta 1, beta 2 and alpha) and an undefined molecule of 37 kDa (beta 3) on certain types of cells. Here we present serological and biochemical evidence that the beta 3 chain is expressed on mouse thymocytes and that it is identical to the CD2 antigen. By immunofluorescence staining and cytofluorographic analysis greater than 95% of thymocytes were positive. Brightly staining cells coincided with cortisone-resistant thymocytes suggesting that mature thymocytes expressed higher levels of the antigen. Biosynthetic labeling of DBA/2 thymocytes with [35S]methionine showed that the size of the CD2 precursor molecule was 43 kDa which was processed to approximately 55-65 kDa in the mature molecule. mAb 12-15 was also reactive with the tunicamycin-treated form of the CD2 antigen suggesting that the cross-reactive epitope was of protein nature. Comparison of different mouse strains indicated that two molecular forms of CD2 exist. On BALB/c thymocytes, the relative mass of the native molecule was approximately 60-70 kDa (CD2.1) and slightly larger than in DBA/2 (CD2.2). Following endoglycosidase F treatment both proteins still showed a slight difference in electrophoretic mobility. Several inbred mouse strains were analyzed for expression of CD2 forms. When mAb 12-15 was used in cytotoxic T lymphocyte inhibition experiments using specific CTL and tumor target cells it was found that the antibody could specifically inhibit CTL-mediated lysis presumably by interfering with CD2 function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564824     DOI: 10.1002/eji.1830190219

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Quantitation of antibody uptake in spontaneous metastases.

Authors:  U Schmid; V Schirrmacher; H Bihl; S Matzku
Journal:  Br J Cancer Suppl       Date:  1990-07

3.  Human CD2 is functional in CD2 transgenic mice.

Authors:  E Monostori; G Lang; D Kioussis; D A Cantrell; R Zamoyska; M H Brown; M J Crumpton
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

4.  Production of multiple murine CD2 receptor constructs using the baculovirus expression vector and a rapid dot-blot assay.

Authors:  A J Kaplan; K D Chavin; L H Qin; H Yagita; J S Bromberg
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

5.  Sex-specific quantitative trait loci govern susceptibility to Theiler's murine encephalomyelitis virus-induced demyelination.

Authors:  Russell J Butterfield; Randall J Roper; Dominic M Rhein; Roger W Melvold; Lia Haynes; Runlin Z Ma; R W Doerge; Cory Teuscher
Journal:  Genetics       Date:  2003-03       Impact factor: 4.562

6.  Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.

Authors:  K D Chavin; L Qin; J Lin; J E Woodward; P Baliga; J S Bromberg
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

7.  Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.

Authors:  L Qin; K D Chavin; Y Ding; J E Woodward; J P Favaro; J Lin; J S Bromberg
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

8.  Expression of L1 cell adhesion molecule is associated with lymphoma growth and metastasis.

Authors:  A Kowitz; G Kadmon; H Verschueren; L Remels; P De Baetselier; M Hubbe; M Schachner; V Schirrmacher; P Altevogt
Journal:  Clin Exp Metastasis       Date:  1993-09       Impact factor: 5.150

9.  Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases.

Authors:  S Matzku; H Krempel; H P Weckenmann; V Schirrmacher; H Sinn; H Stricker
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.

Authors:  L Qin; K D Chavin; J Lin; H Yagita; J S Bromberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.